These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 20058474)
1. Novel agents in the frontline management of multiple myeloma. Loong HH Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474 [TBL] [Abstract][Full Text] [Related]
2. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
4. An update on drug combinations for treatment of myeloma. Srikanth M; Davies FE; Morgan GJ Expert Opin Investig Drugs; 2008 Jan; 17(1):1-12. PubMed ID: 18095914 [TBL] [Abstract][Full Text] [Related]
5. Management of older patients with multiple myeloma. Gay F; Palumbo A Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387 [TBL] [Abstract][Full Text] [Related]
6. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide efficacy in bortezomib-resistant myeloma. Gozzetti A; Crupi R; Defina M; Bocchia M Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907 [No Abstract] [Full Text] [Related]
9. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
10. The role of novel drugs in multiple myeloma. Dimopoulos MA; Kastritis E Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953 [No Abstract] [Full Text] [Related]
11. Treatment of relapsed and refractory myeloma. Kaufman J; Gleason C; Lonial S Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756 [TBL] [Abstract][Full Text] [Related]
13. Lenalidomide for bortezomib-resistant multiple myeloma. Briani C; Berno T; Campagnolo M; Zambello R Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906 [No Abstract] [Full Text] [Related]
14. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related]